Cargando…

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus

Chronic kidney diseases (CKD) and cardiovascular diseases (CVD) are the main complications in type 2 diabetic mellitus (T2DM), increasing the risk of cardiovascular and all-cause mortality. Current therapeutic strategies that delay the progression of CKD and the development of CVD include angiotensi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Ruolin, Xu, Lili, Che, Lin, Liu, Song, Wang, Yangang, Dong, Bingzi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968798/ https://www.ncbi.nlm.nih.gov/pubmed/36860374 http://dx.doi.org/10.3389/fendo.2023.1125693

Ejemplares similares

The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
por: Dong, Bingzi, et al.
Publicado: (2022)

The Emerging Role of Bone-Derived Hormones in Diabetes Mellitus and Diabetic Kidney Disease
por: Li, Yixuan, et al.
Publicado: (2022)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis
por: Ghosal, Samit, et al.
Publicado: (2023)

Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
por: Kim, Dong-Lim, et al.
Publicado: (2023)

Establishment and validation of a clinical model for predicting diabetic ketosis in patients with type 2 diabetes mellitus
por: Qi, Mengmeng, et al.
Publicado: (2022)

Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications
por: Si, Ke, et al.
Publicado: (2021)

Circadian rhythm of plasminogen activator inhibitor-1 and cardiovascular complications in type 2 diabetes
por: Yu, Yongzhuo, et al.
Publicado: (2023)

The Role of Slit-2 in Gestational Diabetes Mellitus and Its Effect on Pregnancy Outcome
por: Wang, Yan, et al.
Publicado: (2022)

Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
por: Palanisamy, Srikanth, et al.
Publicado: (2022)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights
por: Mei, Yongsheng, et al.
Publicado: (2022)

Diabetes mellitus promotes susceptibility to periodontitis—novel insight into the molecular mechanisms
por: Zhao, Mingcan, et al.
Publicado: (2023)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Non-coding RNAs in diabetes mellitus and diabetic cardiovascular disease
por: Li, Chengshun, et al.
Publicado: (2022)

Recent advances in molecular mechanisms of acute kidney injury in patients with diabetes mellitus
por: Infante, Barbara, et al.
Publicado: (2023)

Cardiovascular Magnetic Resonance as Pathophysiologic Tool in Diabetes Mellitus
por: Mavrogeni, Sophie I., et al.
Publicado: (2021)

Human cytomegalovirus infection and its association with gestational diabetes mellitus during pregnancy
por: Wang, Yunyang, et al.
Publicado: (2022)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
por: Jin, Tao, et al.
Publicado: (2023)

Case report: A case of Culler-Jones syndrome caused by a novel mutation of GLI2 gene and literature review
por: Zhang, Yiwen, et al.
Publicado: (2023)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options
por: Zhang, Chunye, et al.
Publicado: (2021)

The role of C-peptide in diabetes and its complications: an updated review
por: Chen, Jintao, et al.
Publicado: (2023)

History of Gestational Diabetes Mellitus in Relation to Cardiovascular Disease and Cardiovascular Risk Factors in US Women
por: Shostrom, Derrick C. V., et al.
Publicado: (2017)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links
por: De Rosa, Salvatore, et al.
Publicado: (2018)

Acetylcarnitine Is Associated With Cardiovascular Disease Risk in Type 2 Diabetes Mellitus
por: Zhao, Shuo, et al.
Publicado: (2021)

Ferroptosis: roles and molecular mechanisms in diabetic cardiomyopathy
por: Zhao, Yangting, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus
por: Jyotsna, FNU, et al.
Publicado: (2023)

Molecular mechanisms underlying the role of hypoxia-inducible factor-1 α in metabolic reprogramming in renal fibrosis
por: Wei, Xuejiao, et al.
Publicado: (2022)

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
por: Zhang, Yaofu, et al.
Publicado: (2022)

Integrative bioinformatics analysis of biomarkers and pathways for exploring the mechanisms and molecular targets associated with pyroptosis in type 2 diabetes mellitus
por: Wang, Wei, et al.
Publicado: (2023)

The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms
por: Zhu, Bing, et al.
Publicado: (2022)

The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality
por: Kumar, Shejil, et al.
Publicado: (2018)

Age at diagnosis, diabetes duration and the risk of cardiovascular disease in patients with diabetes mellitus: a cross-sectional study
por: Yao, Xuelin, et al.
Publicado: (2023)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Accelerated Ovarian Aging Among Type 2 Diabetes Patients and Its Association With Adverse Lipid Profile
por: Wang, Yahao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dt7frflvfrve37hv8f8i80514q